Oncology firm Immunome's Q2 net loss widens as R&D costs rise

Immunome

11/08/2026 21:54

Overview
U.S. targeted oncology firm's Q2 net loss widened as collaboration revenue fell to zero
Research and development expenses rose sharply yr/yr in Q2
Company ended Q2 with $520 mln in cash and marketable securities, expects runway into 2028

Outlook
Immunome expects current cash position to fund operations into 2028
Company plans to submit EU Marketing Authorization Application for varegacestat by end of 2026
FDA PDUFA target action date for varegacestat set for April 28, 2027

Result Drivers
INCREASED R&D SPENDING - Higher research and development expenses driven by advancement of clinical pipeline
CLINICAL TRIAL ACTIVITY - Initiation and progression of multiple clinical trials contributed to higher operating expenses

Company press release: ID:nBw9TgpVMa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.65
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immunome, Inc. is $35.50, about 38.2% above its August 10 closing price of $25.69

Reuters Recommended Reads
Aug 11 - Intensity Therapeutics Q2 net loss widens as R&D costs rise
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)